Interferon (IFN)-alpha has been used to investigate pathways by which innate immune cytokines influence the brain and behaviour. Previous studies suggest that altered basal ganglia function may contribute to IFN-alpha-induced neuropsychological and behavioural changes. To further examine IFN-alpha effects on neuropsychological functions related to basal ganglia (as well as other brain regions), and explore the relationship between altered neuropsychological function and IFN-alpha-induced depression and fatigue, a selected subset of the Cambridge Neuropsychological Test Automated Battery was administered to 32 hepatitis C patients at baseline (Visit 1) and following $12 weeks (Visit 2) of either no treatment (n = 12) or treatment with IFN-alpha plus ribavirin (n = 20). Symptoms of depression and fatigue were assessed using the Montgomery-Asberg Depression Rating Scale and the Multidimensional Fatigue Inventory. Compared to control subjects, patients treated with IFN-alpha/ribavirin exhibited significant decreases in motor speed as measured in the simple and five-choice movement segments of the CANTAB reaction time task and slower response times in the rapid visual information processing task, a task of sustained attention. Decreased motor speed on the five-choice movement segments of the reaction time task was in turn correlated with increased symptoms of depression and fatigue (R = 0.47, p < 0.05 and R = 0.48, p < 0.05, respectively). IFN-alpha/ribavirin treatment had no effects on executive function, decision time in the reaction time task, or target detection accuracy in the sustained attention task. Motor slowing and its correlation with psychiatric symptoms suggest that altered basal ganglia function may contribute to the pathogenesis of IFN-alpha-induced behavioural changes.
Introduction
Interferon (IFN)-alpha is an innate immune cytokine with potent antiviral and anti-proliferative properties that is used to treat viral infections such as hepatitis C and certain cancers including malignant melanoma and renal cell carcinoma (Dorr, 1993; Kirkwood, 2002) . Despite therapeutic efficacy in these illnesses, IFN-alpha administration causes marked behavioural changes that overlap with major depression including depressed mood, anhedonia, anergia/fatigue, psychomotor slowing, cognitive dysfunction, anxiety/irritability, anorexia, sleep alterations and increased sensitivity to pain (Loftis and Hauser, 2004; Maddock et al., 2005; Reichenberg et al., 2005; Asnis and De La Garza, 2006; Lotrich et al., 2007) . Given IFN-alpha's effects on behaviour and its ability to activate the innate immune response including the release of other innate immune cytokines such as interleukin (IL)-6, IFN-alpha has been used as a model to study the influence of innate immune cytokines on the brain. 
